Positive FDA Panel Excites Titan Investors
This article was originally published in Scrip
Executive Summary
Shares of Titan Pharmaceuticals Inc. rocketed more than 42% in morning trading on Jan. 13 a day after the FDA's Psychopharmacologic Drugs Advisory Committee voted 12-5 to back the approval of Probuphine, a matchstick-size subdermal implant intended to deliver buprenorphine to treat opioid dependence, which the company has been developing with privately held Braeburn Pharmaceuticals Inc.